Qilian International Holding Group Ltd. Ordinary Shares - QLI STOCK NEWS

Qilian International Holding Group Limited (Nasdaq: QLI) has signed an exclusive agency agreement with Henan Kangzhiyuan Pharmaceutical Co., Ltd. to enhance sales of its Gan Di Xin^® product, a licorice-based medication. The agreement, effective from April 22, 2021, spans five years and aims to leverage mutual resources for better market penetration. Gan Di Xin^® is known for its innovative formulation and effectiveness as an antitussive and expectorant. The collaboration is expected to significantly boost sales through Kangzhiyuan's extensive national marketing channels.

Qilian International Holding Group Limited (Nasdaq: QLI) announced that 16 of its pharmaceutical products have been added to China's National Reimbursement Drugs List. This list significantly enhances patient access to these medications, including those for coronary heart disease and urinary tract infections. Additionally, 10 of these products are now part of the National Essential Medicines List, further solidifying their market position. The inclusion is expected to boost demand as patients will receive reimbursements for these listed drugs.

Jiuquan, China, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (Nasdaq: QLI) announced that Chairman and CEO, Mr. Zhanchang Xin, received the Outstanding Entrepreneur Award from the Economic and Technological Development Zone of Jiuquan City. This recognition highlights the Company's leadership and innovation in the pharmaceutical and chemical sectors. Mr. Xin emphasized that the award validates the Company's market position and reflects customer enthusiasm for their products, aiming to drive business growth and create long-term value for investors.

Qilian International Holding Group Limited (Nasdaq: QLI) reported a 9% revenue increase to $50 million for the fiscal year ended September 30, 2020, compared to $46.1 million in 2019. Key product segments such as oxytetracycline and heparin drove growth despite challenges from the COVID-19 pandemic. However, gross profit fell 22% to $7.5 million, with a gross margin decrease to 15.1%. Net income attributable to shareholders was $5.1 million, down 5% from the previous year. The company anticipates sustained demand growth in the long run and aims to leverage its recent IPO to pursue growth opportunities.

Qilian International Holding Group Limited (Nasdaq: QLI) announced the upcoming completion of the first phase expansion of its organic fertilizer production facility in Jiuquan City, Gansu Province, expected by March 2021. This expansion aims to triple its production capacity. The company has already secured government bids for organic fertilizer projects in Tibet, Gansu, and Qinghai. Chairman Zhanchang Xin highlighted the significant potential of the organic fertilizer market in China, positioning this segment as a future growth driver for the company.

Qilian International Holding Group Limited (Nasdaq: QLI) announced that underwriters fully exercised their option to purchase an additional 750,000 ordinary shares at $5.00 each during its IPO, totaling gross proceeds of $28.75 million. The shares began trading on January 12, 2021. Proceeds will fund investments in Oxytetracycline API production, an organic-waste treatment facility, Heparin Sodium Preparation facilities, and marketing for Gan Di Xin®. The IPO was managed by Univest Securities, LLC, with SEC registration declared effective on December 30, 2020.

Qilian International Holding Group Limited (Nasdaq: QLI) has completed its initial public offering, selling 5 million ordinary shares at $5.00 each, raising $25 million in gross proceeds. The offering includes a 45-day option for underwriters to purchase an additional 750,000 shares. Proceeds will fund investments in Oxytetracycline API production facilities, a waste treatment facility, and Heparin Sodium Preparation facilities, as well as marketing for Gan Di Xin®. The shares began trading on January 12, 2021.

ATIF Holdings Limited announced that its client, Qilian International Holding Group Limited, has officially launched its ordinary shares on the Nasdaq Global Market as of January 12, 2021. Qilian's initial public offering (IPO) priced 5,000,000 shares at $5.00 each, aiming for gross proceeds of $25 million. Additionally, underwriters have a 45-day option to purchase another 750,000 shares. Qilian operates in pharmaceutical and chemical production in China and has a broad market presence across various provinces.

Qilian International Holding Group Limited announced the pricing of its initial public offering (IPO) of 5,000,000 ordinary shares at $5.00 per share, aiming to raise $25 million. The shares will trade on Nasdaq under the ticker symbol QLI starting January 12, 2021. The company has also granted underwriters a 45-day option to buy an additional 750,000 shares. Proceeds will fund investments in Oxytetracycline production, an organic-waste treatment facility, and marketing for Gan Di Xin. The IPO is expected to close around January 14, 2021.